Metacrine to Host Virtual R&D Day for Analysts and Investors on September 15, 2021
08 sept. 2021 08h05 HE
|
Metacrine, Inc.
Featuring KOL and management discussions on the science of FXR agonists and the Company’s programs in NASH and IBD SAN DIEGO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a...
Metacrine to Present at H.C. Wainwright 23rd Annual Global Investment Conference
07 sept. 2021 08h05 HE
|
Metacrine, Inc.
SAN DIEGO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and...
Metacrine Updates MET642 Clinical Development Milestone and Reports Second-Quarter 2021 Results
12 août 2021 08h05 HE
|
Metacrine, Inc.
Interim data from the Phase 2a trial of MET642 in patients with NASH now expected early in the fourth quarter of 2021Topline results from a Phase 2a trial of MET409 in combination with empagliflozin...
Metacrine to Present at 2021 Canaccord Genuity Growth Conference
09 août 2021 08h05 HE
|
Metacrine, Inc.
SAN DIEGO, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and...
Metacrine and Its Partners to Present Data at the EASL International Liver Congress™ 2021
17 juin 2021 08h05 HE
|
Metacrine, Inc.
SAN DIEGO, June 17, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and...
Metacrine Achieves Full Enrollment for MET409 Phase 2a Combination Trial in Patients With Type 2 Diabetes and NASH
02 juin 2021 08h05 HE
|
Metacrine, Inc.
Topline data expected to be reported in the fourth quarter of 2021 SAN DIEGO, June 02, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering...
Metacrine to Present at 2021 Jefferies Healthcare Conference
26 mai 2021 08h05 HE
|
Metacrine, Inc.
SAN DIEGO, May 26, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal...
Metacrine Achieves Enrollment Target for MET642 Phase 2a Trial Interim Analysis
18 mai 2021 08h05 HE
|
Metacrine, Inc.
Interim data from the first 60 patients with NASH on track to be reported in the fourth quarter of 2021Enrollment continuing for up to 180 patients, with full topline results expected to be reported...
Metacrine Appoints Dr. Julia C. Owens to Its Board of Directors
05 avr. 2021 16h05 HE
|
Metacrine, Inc.
SAN DIEGO, April 05, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and...
Global Non-alcoholic Steatohepatitis Biomarkers Market Accounted for US$ 556.6 Billion in 2019 and is Estimated to be US$ 8177.9 Billion by 2029 and is Anticipated to Register a CAGR of 31.3%
18 août 2020 10h05 HE
|
PMI
Covina, CA, Aug. 18, 2020 (GLOBE NEWSWIRE) -- The report "Global Non-alcoholic Steatohepatitis Biomarkers Market, By Type (Serum Biomarkers, Hepatic Fibrosis Biomarkers, Apoptosis Biomarkers,...